Does statin use cause memory decline in the elderly?

Trends in Cardiovascular Medicine

Volumn 26, Issue 6, 2016, Pages 550-565

  Samaras, Katherine ^a,b   Brodaty, Henry ^a,c   Sachdev, Perminder S ^c,d  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Brain; Brain volume; Cognition; Dementia; Diabetes; Heart; HMGCoA reductase inhibitors; Hypertension; Ischemic heart disease; Magnetic resonance; Memory; Statins; Stroke

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ALZHEIMER DISEASE; CLINICAL OUTCOME; COGNITION; COGNITIVE DEFECT; DEMENTIA; HUMAN; MEMORY DISORDER; META ANALYSIS; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; AGE; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; MALE; MEMORY; MEMORY DISORDERS; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN; COGNITION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEMORY; MEMORY DISORDERS; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84975140633     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2016.03.009     Document Type: Review

References (57)

1. [1] Kristiansen, P.J., Normann, H.K., Norberg, A., Fjelltun, A.M., Skaalvik, M.W., How do people in the early stage of Alzheimer's disease see their future?. Dementia (London), 2015 10.1177/1471301215584223.
2. [2] Sachdev, P.S., Lipnicki, D.M., Kochan, N.A., Crawford, J.D., Thalamuthu, A., Andrews, G., et al. The prevalence of mild cognitive impairment in diverse geographical and ethnocultural regions: the COSMIC collaboration. PloS one, 10, 2015, e0142388.
3. [3] Reisberg, B., Shulman, M.B., Torossian, C., Leng, L., Zhu, W., Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement 6 (2010), 11–24.
4. [4] Petersen, R.C., Roberts, R.O., Knopman, D.S., Boeve, B.F., Geda, Y.E., Ivnik, R.J., et al. Mild cognitive impairment: ten years later. Arch Neurol 66 (2009), 1447–1455.
5. [5] Norton, S., Matthews, F.E., Barnes, D.E., Yaffe, K., Brayne, C., Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol 13 (2014), 788–794.
6. [6] Gorelick, P.B., Scuteri, A., Black, S.E., Decarli, C., Greenberg, S.M., Iadecola, C., et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 42 (2011), 2672–2713.
7. [7] Cholesterol Treatment Trialists Collaboraton, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
8. [8] Cholesterol Treatment Trialists Collaboraton, Kearney, P.M., Blackwell, L., Collins, R., Keech, A., Simes, J., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008), 117–125.
9. [9] Cholesterol Treatment Trialists Collaboraton, Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
10. [10] Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:25 Suppl 2 (2014), S1–S45.
11. [11] Golomb, B.A., McGraw, J.J., Evans, M.A., Dimsdale, J.E., Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 30 (2007), 669–675.
12. [12] FDA. FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs. 07.03.12, 2014. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm [accessed 22.04.14].
13. [13] Wolozin, B., Wang, S.W., Li, N.C., Lee, A., Lee, T.A., Kazis, L.E., Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med, 5, 2007, 20.
14. [14] Parikh, N.M., Morgan, R.O., Kunik, M.E., Chen, H., Aparasu, R.R., Yadav, R.K., et al. Risk factors for dementia in patients over 65 with diabetes. Int J Geriatr Psychiatry 26 (2011), 749–757.
15. [15] Cramer, C., Haan, M.N., Galea, S., Langa, K.M., Kalbfleisch, J.D., Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71 (2008), 344–350.
16. [16] Haag, M.D., Hofman, A., Koudstaal, P.J., Stricker, B.H., Breteler, M.M., Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The rotterdam study. J Neurol Neurosurg Psychiatry 80 (2009), 13–17.
17. [17] Sparks, D.L., Kryscio, R.J., Sabbagh, M.N., Connor, D.J., Sparks, L.M., Liebsack, C., Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 5 (2008), 416–421.
18. [18] Ancelin, M.L., Carriere, I., Barberger-Gateau, P., Auriacombe, S., Rouaud, O., Fourlanos, S., et al. Lipid lowering agents, cognitive decline, and dementia: the three-city study. J Alzheimers Dis 30 (2012), 629–637.
19. [19] Arvanitakis, Z., Schneider, J.A., Wilson, R.S., Bienias, J.L., Kelly, J.F., Evans, D.A., et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70:19 Pt 2 (2008), 1795–1802.
20. [20] Bettermann, K., Arnold, A.M., Williamson, J., Rapp, S., Sink, K., Toole, J.F., et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis 21 (2012), 436–444.
21. [21] Rea, T.D., Breitner, J.C., Psaty, B.M., Fitzpatrick, A.L., Lopez, O.L., Newman, A.B., et al. Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol 62 (2005), 1047–1051.
22. [22] Szwast, S.J., Hendrie, H.C., Lane, K.A., Gao, S., Taylor, S.E., Unverzagt, F., et al. Association of statin use with cognitive decline in elderly African Americans. Neurology 69 (2007), 1873–1880.
23. [23] Zandi, P.P., Sparks, D.L., Khachaturian, A.S., Tschanz, J., Norton, M., Steinberg, M., et al. Do statins reduce risk of incident dementia and Alzheimer disease? The cache county study. Arch Gen Psychiatry 62 (2005), 217–224.
24. [24] Deschaintre, Y., Richard, F., Leys, D., Pasquier, F., Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73 (2009), 674–680.
25. [25] Hajjar, I., Schumpert, J., Hirth, V., Wieland, D., Eleazer, G.P., The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57 (2002), M414–M418.
26. [26] Masse, I., Bordet, R., Deplanque, D., Al Khedr, A., Richard, F., Libersa, C., et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 76 (2005), 1624–1629.
27. [27] Rosenberg, P.B., Mielke, M.M., Tschanz, J., Cook, L., Corcoran, C., Hayden, K.M., et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry 16 (2008), 883–892.
28. [28] Winblad, B., Jelic, V., Kershaw, P., Amatniek, J., Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials. Drugs Aging 24 (2007), 57–61.
29. [29] Heart Protection Study Collaborative Group, MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
30. [30] Trompet, S., van Vliet, P., de Craen, A.J., Jolles, J., Buckley, B.M., Murphy, M.B., et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 257 (2010), 85–90.
31. [31] Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L., Buckley, B.M., Cobbe, S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002), 1623–1630.
32. [32] Simons, M., Schwarzler, F., Lutjohann, D., von Bergmann, K., Beyreuther, K., Dichgans, J., et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52 (2002), 346–350.
33. [33] Feldman, H.H., Doody, R.S., Kivipelto, M., Sparks, D.L., Waters, D.D., Jones, R.W., et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74 (2010), 956–964.
34. [34] Sano, M., Bell, K.L., Galasko, D., Galvin, J.E., Thomas, R.G., van Dyck, C.H., et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77 (2011), 556–563.
35. [35] Summers, M.J., Oliver, K.R., Coombes, J.S., Fassett, R.G., Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy 27 (2007), 183–190.
36. [36] Muldoon, M.F., Ryan, C.M., Sereika, S.M., Flory, J.D., Manuck, S.B., Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 117 (2004), 823–829.
37. [37] Berk-Planken, I., de Konig, I., Stolk, R., Jansen, H., Hoogerbrugge, N., Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care 25 (2002), 1250–1251.
38. [38] Higgins, J.P., Altman, D.G., Gotzsche, P.C., Jüni, P., Moher, D., Oxman, A.D., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J, 343, 2011, d5928.
39. [39] Kaptchuk, T.J., The double-blind, randomized, placebo-controlled trial: gold standard or golden calf?. J Clin Epidemiol 54 (2001), 541–549.
40. [40] Prasad, V., Berger, V.W., Hard-wired bias: how even double-blind, randomized controlled trials can be skewed from the start. Mayo Clin Proc 90 (2015), 1171–1175.
41. [41] Sparks, D.L., Sabbagh, M.N., Connor, D.J., Lopez, J., Launer, L.J., Browne, P., et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62 (2005), 753–757.
42. [42] Richardson, K., Schoen, M., French, B., Umscheid, C.A., Mitchell, M.D., Arnold, S.E., et al. Statins and cognitive function: a systematic review. Ann Intern Med 159 (2013), 688–697.
43. [43] Routledge, P.A., O'Mahony, M.S., Woodhouse, K.W., Adverse drug reactions in elderly patients. Br J Clin Pharmacol 57 (2004), 121–126.
44. [44] Rey, A., L'examen Clinique en Psychologie, 1964, Presses Universitaires de France, Paris.
45. [45] Wechsler, D., Wechsler Memory Scale—Version III (WMS-III). Psychological Corporation, 1997, The Psychological Corporation, Harcourt Brace & Co, San Antonio.
46. [46] Benton, A., Sivan, A.B., Spreen, O., Der Benton Test Manual, 1996, Huber, Bern.
47. [47] Benton, A., Problems of test construction in the field of aphasia. Cortex 3 (1967), 32–58.
48. [48] Reitan, R.M., Wolfson, D., The Halstead-Reitan Neuropsychological Test Battery: Theory And Clinical Interpretation, 1985, Neuropsychology Press, Tucson, AZ.
49. [49] Wechsler, D., Wechsler Adult Intelligence Scale—Version III (WAIS-III), 1997, Psychological Corporation, Harcourt Brace & Co, San Antonio.
50. [50] Spreen, O, Benton, AL., Neurosensory Center Comprehensive Examination for Aphasia: Manual of Instructions (NCCEA), 1969, University of Victoria, Victoria.
51. [51] Kaplan, E., The Boston Naming Test, 2001, Lippincott Williams & Wilkins, Philadelphia.
52. [52] Beydoun, M.A., Beason-Held, L.L., Kitner-Triolo, M.H., Beydoun, H.A., Ferrucci, L., Resnick, S.M., et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health 65 (2011), 949–957.
53. [53] Hippisley-Cox, J., Coupland, C., Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. Br Med J, 340, 2010, c2197.
54. [54] Smeeth, L., Douglas, I., Hall, A.J., Hubbard, R., Evans, S., Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67 (2009), 99–109.
55. [55] Li, G., Shofer, J.B., Rhew, I.C., Kukull, W.A., Peskind, E.R., McCormick, W., et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc 58 (2010), 1311–1317.
56. [56] Yaffe, K., Barrett-Connor, E., Lin, F., Grady, D., Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59 (2002), 378–384.
57. [57] Prajapati, S., Desai, C.K., Dikshit, R.K., An evaluation of the effect of atorvastatin on memory and psychomotor functions in hypertensive patients. J Postgrad Med 57 (2011), 291–297.